Date:
April 5, 2021
Issue #:
1621
Summary:
The FDA has approved the oral tyrosine kinase inhibitor
ripretinib (Qinlock – Deciphera) for treatment of adults
with advanced gastrointestinal stromal tumors (GISTs)
who have previously received treatment with ≥3 kinase
inhibitors, including imatinib (Gleevec, and generics).
ripretinib (Qinlock – Deciphera) for treatment of adults
with advanced gastrointestinal stromal tumors (GISTs)
who have previously received treatment with ≥3 kinase
inhibitors, including imatinib (Gleevec, and generics).
